Innovative ETFs Channel Invesco’s Rene Reyna on Biotech’s Rally and the Potential for Future Growth By Elle CarusoAugust 19, 2022
Nasdaq Investment Intelligence Channel Pfizer Biohaven Acquisition Sparks Hope of More Biotech M&A By Tom LydonMay 12, 2022
Nasdaq Investment Intelligence Channel Battered Biotech Space Now Unbelievably Inexpensive By Tom LydonMay 6, 2022
Nasdaq Investment Intelligence Channel Cap-Weighting Crucial When Indexing Biotech By James ComtoisJanuary 25, 2022
Nasdaq Investment Intelligence Channel Biotech Firms Partner to Advance Therapeutic Medicine By James ComtoisJanuary 13, 2022
Nasdaq Investment Intelligence Channel Biotech Stocks and ETFs Can Get Their Grooves Back By Tom LydonJanuary 11, 2022
ETF Education channel Expect More Biotech Consolidation Activity in 2022 By Tom LydonDecember 14, 2021
Innovative ETFs Channel Moderna’s Omicron Booster Strategy Lifts Biotechnology ETFs By Max ChenNovember 29, 2021
Nasdaq Investment Intelligence Channel New Biotechnology ETF Could Be a Stellar Second Half Idea By Tom LydonJuly 1, 2021
Innovative ETFs Channel A Biotech ETF to Track Nasdaq’s Industry-Setting Benchmark By Max ChenJune 30, 2021
Nasdaq Investment Intelligence Channel New Invesco ETF Joins the Gold Standard of Biotech Benchmarks By Tom LydonJune 11, 2021
